ClinicalTrials.gg
Active, not recruitingNCT05562947HUTONGUpdated Sep 1, 2026

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

A Phase 3 interventional study of PDS With Ranibizumab (100 mg/mL) and Ranibizumab (10 mg/mL) in Neovascular Age-related Macular Degeneration and nAMD, sponsored by Hoffmann-La Roche. Active, not recruiting at 14 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Planned enrollment
61st of 124
68 · median 64
Started
2024
with 2 others
Phase 3
31 of 125
2 open now
Registered
120th of 125
by date
Lead sponsor
5 of 125
Hoffmann-La Roche

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 61st largest by planned enrollment of the 124 interventional ones that give a count, is one of 3 that started in 2024, is one of 31 in phase 3, and was the 120th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and PK of ranibizumab 100 milligrams per milliliter (mg/mL) delivered every 24 weeks (Q24W) via the PDS implant compared with ranibizumab 0.5 milligrams (mg) delivered every 4 weeks (Q4W) as intravitreal (IVT) injection in Chinese participants with nAMD.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
  • nAMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Initial diagnosis of nAMD within 9 months prior to the screening visit
  • Previous treatment with at least three anti-vascular endothelial growth factor (VEGF) IVT injections for nAMD per standard-of-care (SOC) within 6 months prior to the screening visit
  • Demonstrated response to prior anti-VEGF IVT treatment since diagnosis
  • Availability of historical VA data prior to the first anti-VEGF treatment for nAMD up to the screening visit
  • BCVA of 34 letters or better (20/200 or better approximate Snellen equivalent), using Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters
  • All subtypes of nAMD lesions are permissible
  • Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by the central reading center of fundus photography (FP), fluorescein angiography (FA), indocyanine green angiography (ICGA), fundus autofluorescence (FAF), and optical coherence tomography (OCT) images

Exclusion criteria

Exclusion Criteria:

A. Prior Ocular Treatment Study Eye

  • History of vitrectomy surgery, submacular surgery, or other surgical intervention, all for AMD
  • Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy
  • Previous treatment with IVT injection or corticosteroid implants
  • Previous intraocular device implantation (not including intraocular lens implants)
  • Previous laser (any type) used for age-related macular degeneration (AMD) treatment
  • Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit
  • Prior treatment with IVT treatments for geographic atrophy
  • Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant

Either Eye

  • Prior treatment with brolucizumab
  • Prior gene therapy for nAMD or other ocular diseases
  • Previous participation in any ocular disease studies of drugs and/or devices, within 3 months or five elimination half-lives of the investigational therapy, whichever is longer, preceding the screening visit

B. Choroidal Neovascularization (CNV) Lesion Characteristics

Study Eye

  • Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area (1.27 millimeter square [mm\^2]) in size at screening
  • Subfoveal fibrosis or subfoveal atrophy

Either Eye • CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia

C. Concurrent Ocular Conditions Study Eye

  • Retinal pigment epithelial tear
  • Any concurrent intraocular condition
  • Active intraocular inflammation (grade trace or above)
  • History of vitreous hemorrhage
  • History of rhegmatogenous retinal detachment
  • History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the randomization visit
  • History of pars plana vitrectomy surgery
  • Aphakia or absence of the posterior capsule
  • Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia
  • Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery
  • Intraocular surgery (including cataract surgery) within 3 months preceding the randomization visit
  • Uncontrolled ocular hypertension or glaucoma
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
  • History of corneal transplant

Fellow (Non-Study) Eye

  • Non-functioning fellow eye

Either Eye

  • Any history of uveitis
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Implant Arm

    Participants will have the implant (pre-filled intraoperatively with ranibizumab 100 mg/mL) surgically inserted on Day 1. After Day 1, participants in the implant arm will attend monthly study visits, and receive implant refill-exchanges with ranibizumab 100 mg/mL at Week 24 and Week 48. At the Week 48 study visit, participants will move to the long -term extension phase of the study and continue receiving refill-exchanges Q24W until the end of study. Participants will attend monthly visits up to Week 96 and bi-monthly visits thereafter, followed by visits every two months until study completion.

    Device: PDS With Ranibizumab (100 mg/mL)

  • Experimental
    IVT Arm

    Participants will receive IVT ranibizumab 0.5 mg injections starting on Day 1. Participants will receive IVT ranibizumab 0.5 mg Q4W until Week 44. At the Week 48 study visit, participants will receive the PDS implant (pre-filled intraoperatively with ranibizumab 100 mg/mL), move to the long-term extension phase of the study and receive Q24W refill exchanges until the end of study. If participants are unable to attend the Week 48 visit due to extenuating circumstances, they should return no later than the next scheduled visit (Week 52), when they will receive the PDS implant. Participants will attend monthly visits up to Week 96 and bi-monthly visits thereafter, followed by visits every two months until study completion.

    Device: PDS With Ranibizumab (100 mg/mL) · Drug: Ranibizumab (10 mg/mL)

Interventions

  • DevicePDS With Ranibizumab (100 mg/mL)

    Participants randomized to the implant arm will have the implant (filled prior to implantation with approximately 20 microliters (μL) of the 100 mg/mL formulation of ranibizumab \[approximately 2 mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit, or at Week 48 visit for participants randomized to the IVT arm. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed 24-week intervals.

  • DrugRanibizumab (10 mg/mL)

    Drug page: Ranibizumab

    Participants in the IVT arm will receive their first IVT injection of 50 μL of the 10 mg/mL ranibizumab (0.5 mg dose) at the Day 1 visit, which will occur at the conclusion of the randomization visit. Afterwards, participants will receive IVT ranibizumab injections of 50 μL of the 10 mg/mL formulation Q4W at each scheduled study visit until Week 44 and bi-monthly visits thereafter, followed by visits every two months until study completion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best-corrected Visual Acuity (BCVA) Score Averaged Over Weeks 36 and 40, as Assessed Using the ETDRS Visual Acuity (VA) Chart at a Starting Distance of 4 Meters

    Time frame: Baseline up to Week 40

Secondary outcomes

  1. Change From Baseline in BCVA Score Over Time

    Time frame: Baseline up to Week 144

  2. Proportion of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse Averaged Over Weeks 36 and 40

    Time frame: Baseline up to Week 40

  3. Proportion of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse Averaged Over Weeks 44 and 48

    Time frame: Baseline up to Week 48

  4. Proportion of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Averaged over Weeks 36 and 40

    Time frame: Baseline up to Week 40

  5. Proportion of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Averaged Over Weeks 44 and 48

    Time frame: Baseline up to Week 48

  6. Proportion of Participants Who Gain ≥ 0 Letters in BCVA Score From Baseline Averaged Over Weeks 36 and 40

    Time frame: Baseline up to Week 40

  7. Proportion of Participants Who Gain ≥ 0 Letters in BCVA Score From Baseline Averaged Over Weeks 44 and 48

    Time frame: Baseline up to Week 48

  8. Proportion of Participants Who Lose < 10 or < 5 Letters in BCVA Score From Baseline Averaged Over Weeks 36 and 40

    Time frame: Baseline up to Week 40

  9. Proportion of Participants Who Lose < 10 or < 5 Letters in BCVA Score From Baseline Averaged Over Weeks 44 and 48

    Time frame: Baseline up to Week 48

  10. Change From Baseline in Center Point Thickness (CPT) at Week 36

    CPT is retinal thickness in the center point of the fovea measured between the internal limiting membrane and the inner third of the retinal pigment epithelium layer. CPT will be measured using optical coherence tomography (OCT).

    Time frame: Baseline and Week 36

  11. Change From Baseline in Central Subfield Thickness (CST) at Week 36

    CST is defined as the average thickness of the central 1 millimeter (mm) circle of the ETDRS grid centered on the fovea. CST will be measured using OCT.

    Time frame: Baseline and Week 36

  12. Change From Baseline in CPT at Week 44

    CPT is retinal thickness in the center point of the fovea measured between the internal limiting membrane and the inner third of the retinal pigment epithelium layer. CPT will be measured using OCT.

    Time frame: Baseline and Week 44

  13. Change From Baseline in CST at Week 44

    CST is defined as the average thickness of the central 1 mm circle of the ETDRS grid centered on the fovea. CST will be measured using OCT.

    Time frame: Baseline and Week 44

  14. Proportion of Participants in the Implant Arm Who do not Undergo Supplemental Treatment With IVT Ranibizumab 0.5 mg Before the First, Second, Third, Fourth, Fifth, and Sixth Fixed Refill-exchange Intervals

    Time frame: Baseline up to 144 weeks

  15. Proportion of Participants in the Implant Arm Who do not Undergo a Supplemental Treatment that Requires Subsequent Additional Supplemental Treatments During the Study

    Time frame: Baseline up to 144 weeks

  16. Percentage of Participants With Adverse Events (AEs)

    Time frame: Baseline up to 144 weeks

  17. Percentage of Participants With Adverse Events of Special Interest (AESIs)

    Time frame: Baseline up to 144 weeks

  18. Duration of AESIs

    Time frame: Baseline up to 144 weeks

  19. Percentage of Participants With Ocular AESIs During the Post-operative Period and Follow-up Period

    Time frame: Post-operative period: up to 37 days after initial implantation Follow-up period: > 37 days after implantation surgery (up to 144 weeks)

  20. Percentage of Participants Who Received PDS Affected With Adverse Device Effects (ADEs)

    Time frame: Baseline up to 144 weeks

  21. Percentage of Participants Who Received PDS Affected With Anticipated Serious Adverse Device Effects (ASADEs)

    Time frame: Baseline up to 144 weeks

  22. Duration of ASADEs

    Time frame: Baseline up to 144 weeks

  23. Number of Device Deficiencies

    Time frame: Baseline up to 144 weeks

  24. Observed Serum Ranibizumab Concentrations at Specified Timepoints

    Time frame: Implant Arm: Weeks 4, 12, 24, 28, 36, 48, 96, 144 and early study termination (EST) visit; IVT Arm: Weeks 4, 24, 36, 48, 52, 60, 72, 76, 84, 96, 144 & EST visit (up to 156 weeks)

  25. Area Under the Concentration Time Curve (AUC) From 0-24 Weeks

    Time frame: Baseline, Weeks 4, 12, and 24

  26. Maximum Serum Concentration (Cmax) of Ranibizumab

    Time frame: Implant Arm: Weeks 4, 12, 24, 28, 36, 48, 96, 144 & EST visit; IVT Arm: Weeks 52, 60, 72, 76, 84, 96, 144, & EST visit (up to 156 weeks)

  27. Minimum Serum Concentration (Cmin) of Ranibizumab

    Time frame: Implant Arm: Weeks 4, 12, 24, 28, 36, 48, 96, 144, & EST visit; IVT Arm: Weeks 52, 60, 72, 76, 84, 96, 144, & EST visit (up to 156 weeks)

  28. Number of Participants With Anti-drug Antibodies (ADAs) to Ranibizumab

    Time frame: Implant Arm: Baseline; Weeks 4, 24, 36, 48, 96, 144 & EST visit; IVT Arm: Baseline, Weeks 4, 24, 36, 48, 52, 72, 96, 144 & EST visit (up to 156 weeks)

  29. Number of Participants With Treatment-emergent ADAs to Ranibizumab During the Study

    Time frame: Implant Arm: Weeks 4, 24, 36, 48, 96, 144, & EST visit; IVT Arm: Weeks 4, 24, 36, 48, 52, 72, 96, 144, & EST visit (up to 156 weeks)

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 36 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 36 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Oct 3, 2022
StartActual
Jun 17, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jul 31, 2029
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05562947
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Jun 17, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Sep 1, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion